Description
While strong evidence shows APOE4 increases amyloid pathology, the precise molecular pathways remain unclear. Understanding these mechanisms is critical for developing targeted therapeutic interventions that could prevent or delay amyloid accumulation in APOE4 carriers.
Gap type: unexplained_observation Source paper: Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. (2019, Nat Rev Neurol, PMID:31367008)
Resolution criteria
Resolution requires: (1) Lipidomics or mass spectrometry comparison of APOE4 vs APOE2/E3 lipidation status in human CSF or brain tissue showing >=2-fold difference in APOE particle number or lipid composition; (2) Functional assays demonstrating that specific lipid modification alters APOE-A-beta binding affinity (KD) or A-beta aggregation kinetics; (3) In vivo validation: APOE4 mice crossed with APOE-lipidation mutant lines showing that restoring normal lipidation reduces amyloid to APOE2/E3 levels. APOE genotype associations without mechanistic lipid-based explanation are insufficient.
Evidence summary
Resolved by hypothesis h-51e7234f: APOE-Dependent Autophagy Restoration. Score: 0.877. Supporting PMIDs: 31578018, 34031601, 33692541, 31235664, 29566236.